Skip to main content
. Author manuscript; available in PMC: 2019 Nov 15.
Published in final edited form as: Clin Cancer Res. 2019 Feb 5;25(10):2975–2987. doi: 10.1158/1078-0432.CCR-18-3160

Figure 2.

Figure 2.

Changes from baseline in phospho-AKT and Ki-67 levels following treatment with alpelisib plus letrozole or placebo plus letrozole. A, phospho-AKT level at baseline and Cycle 1 Day 15 for each patient; B, mean percentage change from baseline in phospho-AKT level at Cycle 1 Day 15; C, mean percentage change from baseline in phospho-AKT level at end of treatment; D, Ki-67 level at baseline and Cycle 1 Day 15 for each patient; E, mean percentage change from baseline in Ki-67 level at Cycle 1 Day 15; F, mean percentage change from baseline in Ki-67 level at end of treatment.